Empatica's New Wearable Technology for Enhanced Parkinson's Monitoring Receives FDA Approval
Empatica's Groundbreaking FDA Clearance for Parkinson's Monitoring
In a significant advancement for the treatment and monitoring of Parkinson's disease, Empatica has announced that its Health Monitoring Platform has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA). This innovative leap builds on the company's previous acquisition of PKG Health in 2025, thereby expanding Empatica's commitment to developing clinical-grade wearable technology specifically aimed at Parkinson's monitoring.
The Empatica Health Monitoring Platform is not just another wearable device; it integrates seamlessly into patient care, offering a continuous monitoring solution that provides objective data on a patient's symptoms over time. This new platform enhances the capabilities established in Empatica’s previous efforts in monitoring conditions like epilepsy and sleep disorders.
Bridging the Gap in Parkinson's Care
Matteo Lai, CEO and co-founder of Empatica, emphasizes the critical impact of this technology on Parkinson’s care, stating, “This clearance marks an important step forward. We are bringing objective monitoring into a platform designed for a great user experience and scale.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.